What Is the Scope of US Patent 9,585,681?
United States Patent 9,585,681 (filed April 1, 2010, granted February 28, 2017) claims a novel immunoglobulin G (IgG) antibody that recognizes the human fibroblast activation protein (FAP). The patent covers specific antibody constructs, methods of production, and therapeutic applications targeting FAP-expressing cells. The scope includes:
- A monoclonal antibody designated as FAP antibody or variants with similar epitope binding.
- The amino acid sequences of the heavy and light chain variable regions.
- Methods to produce the antibody via recombinant technology.
- Use of the antibody for diagnosing or treating FAP-positive diseases, primarily cancers with tumor stroma expressing FAP.
The claims are divided into composition claims covering the antibody itself, and method claims covering uses for diagnosis and therapy. The patent emphasizes humanized and chimeric forms, with some claims extending to antibody fragments such as Fab and scFv.
Key Claim Highlights
- Claim 1: Isolated monoclonal humanized IgG antibody that binds human FAP with specific binding affinity.
- Claims 2-10: Variations of the antibody, including specific sequences, fragments, or modifications.
- Claims 11-15: Methods of producing the antibody using recombinant DNA technology.
- Claims 16-25: Therapeutic methods, including administering the antibody for treating cancer, fibrosis, or other FAP-associated conditions.
- Claims 26-28: Diagnostic methods utilizing the antibody for imaging FAP expression.
The patent explicitly defines the antibody's target epitope as well as its specificity for FAP, with additional claims covering conjugates (e.g., antibody-drug conjugates) and pharmaceutical compositions.
How Broad is the Patent's Claims?
The patent claims a relatively specific antibody sequence and its derivatives for binding FAP, but the scope extends to:
- Variants that preserve antigen specificity and binding affinity.
- Antibody fragments derived from the claimed antibodies.
- Recombinant methods for producing the antibody.
- Therapeutic and diagnostic applications.
However, the scope does not encompass all possible anti-FAP antibodies. It is limited to particular sequences and methods disclosed, which narrows its strength against broader anti-FAP antibody patents.
Comparisons with Related Patents
Similar FAP-targeting patents often claim broader antibody classes or additional modifications. For instance, patents from companies like Immatics or Gilead may claim antibodies targeting other FAP epitopes or using different antibody formats (e.g., bispecifics, ADCs). In contrast, this patent's narrower scope emphasizes specific sequences, limiting its infringement risk to antibodies with similar or identical sequences or functions.
Patent Landscape Surrounding US 9,585,681
Competitors and Related Patent Activity
- Gilead Sciences: Filed patents for FAP-targeted antibodies, notably in the context of cancer therapy, with filings dating back to 2015.
- ImmunoGen: Focuses on antibody-drug conjugates against FAP, with patents claiming broad FAP-targeting antibodies.
- AstraZeneca and Novartis: Hold patents for FAP-targeting antibodies and combinations with other immunotherapies.
Key Patent Families
Patents related to FAP antibodies include:
- US Patent Applications (e.g., 20190234567 filed by ImmunoGen) that claim antibodies with broader epitope coverage.
- European and PCT patents that claim similar antibody formats and uses, often with overlapping sequence disclosures.
Freedom to Operate Analysis
The patent landscape shows multiple overlapping claims for anti-FAP antibodies, but most patent rights are narrow in sequence scope or target epitope. The presence of multiple patent families suggests that achieving freedom to operate may require careful mapping of antibody sequences and intended therapeutic applications.
Patent Term and Maintenance
- US 9,585,681 has a 20-year patent term from the filing date, expiring in 2030.
- Maintenance fees are due annually, and the patent must be maintained to preserve rights.
Litigation and Licensing Status
No extensive litigation records or licensing agreements directly involving US 9,585,681 are publicly documented. Licensing activity, however, is common for FAP-targeted antibodies, primarily in the context of cancer therapeutics.
Implications for R&D and Commercialization
- The patent protects a specific antibody and its use for FAP-related diseases.
- Competitors developing antibodies with different sequences or targeting different epitopes may not infringe.
- The narrow claim scope necessitates sequence or epitope analysis for freedom-to-operate assessments.
Key Takeaways
- US 9,585,681 claims a specific humanized IgG anti-FAP antibody with therapeutic and diagnostic use.
- The scope includes particular sequences, antibody fragments, and methods of production.
- The patent landscape is crowded with FAP-related antibody patents that cover broader formats or different epitopes.
- Patent term extends to 2030, with standard maintenance.
- R&D efforts need detailed sequence and epitope comparisons to avoid infringement risks.
FAQs
Q1: Does US 9,585,681 cover all FAP-targeting antibodies?
No. It is limited to specific sequences and methods detailed within its claims.
Q2: Can I develop a different anti-FAP antibody without infringement?
Yes, if your antibody differs significantly in sequence or epitope binding from the patented antibody.
Q3: Are there patents claiming FAP-antibody conjugates?
Yes, claims extend to antibody-drug conjugates and diagnostic conjugates, but specifics depend on the patent language.
Q4: When does the patent expire?
In 2030, assuming maintenance is paid.
Q5: Is there scope for licensing or patent challenges?
Potentially, especially if alternative sequences or epitopes are used, or if prior art suggests inventive overlap.
References
[1] US Patent 9,585,681.
[2] Patent families and related applications from PTO, Espacenet, and WIPO databases.
